China-Only Studies Are ‘Problematic,’ US FDA’s Pazdur Says Ahead Of Lilly/Innovent PD-1 Inhibitor Review

 
• By Kate Rawson
Richard Pazdur speaks at BioPharma Congress in December 2021 (screenshot)
OCE Director Richard Pazdur wants China to join Project Orbis. • Source: screenshot

More from Clinical Trials

More from R&D